All-trans retinoic acid (ATRA) is an effective drug for the induction therapy of acute promyelocytic leukemia. However, the treatment is associated with adverse events such as retinoic acid syndrome (RAS) in some patients, whose histologic characteristics included organ infiltration by leukemic cells. Matrix metalloproteinase 2 (MMP-2) is often upregulated in tumor cells and plays a role in tumor cell migration and invasion by degrading the extracellular matrix. In this study, we examined the possible modulatory effects of ATRA on MMP-2 expression and secretion in human myeloid leukemia cell line THP-1. The cells were treated with various concentrations of ATRA, and MMP-2 expression and secretion were examined. MMP-2 expression and secretion started to increase with ATRA concentration as low as 0.1 nM and gradually increased thereafter. Agonists of retinoic acid receptor (RAR) or retinoid X receptor (RXR) alone could enhance MMP-2 secretion, and RAR or RXR antagonists alone could reverse ATRA-induced MMP-2 secretion. ATRA increased intracellular calcium ion levels, and a calcium-channel blocker inhibited ATRA-induced MMP-2 secretion. Dexamethasone suppressed ATRA-induced MMP-2 secretion. Our results suggest that ATRA enhances MMP-2 expression and secretion in human myeloid leukemia THP-1 cells in a calcium ion dependent manner through RAR/RXR signaling pathways, and this enhanced expression and secretion may be associated with the possible mechanisms of RAS.
Previous in vitro studies showed that ATRA inhibited MMP-2 expression in human cancer cell lines from glioblastoma [23, 24], breast cancer [25], lung cancer [26], ovarian cancer [27], chondrosarcoma [28], and osteosarcoma [29], but it did not affect [30] or enhance [31] MMP-2 expression in neuroblastoma cell line. However, the role of ATRA in the regulation of MMP-2 expression in myeloid leukemic cells has not been clarified. The purpose of this study was to investigate the possible modulatory effects of ATRA on MMP-2 expression and secretion in human myeloid leukemia THP-1 cells.

2. Materials and Methods

2.1. Reagents and Chemicals. ATRA, RARα agonist BMS755, RARα antagonist BMS95614, retinoid X receptor (RXR) α agonist LG100268, and pan RXR antagonist UVI3003 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibiotic-antimycotic, HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid) buffer, and β-mercaptoethanol were purchased from Invitrogen Corp (Gibco BRL, MD, USA).

2.2. Cell Culture and Treatment. THP-1 cells (Korean Cell Line Bank, Seoul, Korea) were maintained in RPMI 1640 culture medium (Welgene Inc., Daegu, Korea) with 10% heat-inactivated fetal bovine serum (FBS) and culture medium (Welgene Inc., Daegu, Korea) were maintained in RPMI 1640 containing 0.1% gelatin type A. After electrophoresis, the gel was washed with 2.5% Triton X-100, followed by incubation with developing buffer overnight at 37°C. The gel was then stained with Coomassie brilliant blue and destained with a methanol-acetic acid solution. The gel was visualized on a light box.

2.3. Western Blot Analysis. To measure the secreted MMP-2 proteins, the culture supernatants were collected by centrifugation at 400 x g for 5 min, and then concentrated using an Amicon Ultra-15 Centrifugal Filter Unit, 10 kDa cut-off (Millipore Corp., Billerica, MA, USA) at 2000 x g for 20 min. The supernatants were collected and the protein concentrations were measured with the Qubit fluorometer (Invitrogen Corp). Five micrograms of protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto a polyvinylidene difluoride (PVDF) membrane (Millipore Corp.). The membrane was blocked with 5% BSA in 1X TBST (2.68 mM KCl, 137 mM NaCl, 25 mM Tris-HCl, and 0.05% Tween 20). Next, the membrane was probed with an anti-MMP-2 (42-5D11, Millipore Corp.) or an anti-β actin antibody (Santa Cruz Biotechnology Inc., Dallas, TX, USA). The proteins of interest were detected with an HRP-conjugated goat anti-mouse IgG antibody (sc-2055; Santa Cruz Biotechnology Inc.) or donkey anti-goat IgG antibody (sc-2020; Santa Cruz Biotechnology Inc.) and visualized with ECL-West-Q Pico ECL Solution from GenDEPOT (Barker, TX, USA) using the ChemiDoc MP System (Bio-Rad, Hercules, CA, USA).

2.4. Gelatin Zymography. The THP-1 cells were cultured in a serum-free medium for 48 h with or without 1 μM ATRA. The obtained conditioned media were mixed with nonreducing sample buffer and incubated at room temperature for 10 min. The samples were then loaded onto a 10% acrylamide gel containing 0.1% gelatin type A. After electrophoresis, the gel was washed with 2.5% Triton X-100, followed by incubation with developing buffer overnight at 37°C. The gel was then stained with Coomassie brilliant blue and destained with a methanol-acetic acid solution. The gel was visualized on a light box.

2.5. Flow Cytometry. To determine the cell surface expression of MMP-2, the cells were first incubated with a purified anti-MMP2 antibody (42-5D11, EMD Millipore Corporation) for 30 min and then with the phycoerythrin-conjugated secondary antibody (Mouse IgG, CLCC35004, Cedarlane Lab, Burlington, Ontario, Canada) at 4°C for 30 min. After washing twice with phosphate buffered saline (PBS), the cells were resuspended in PBS and analyzed on a Cytomics FC500 MLP (Beckman Coulter Inc., Fullerton, CA, USA).

2.6. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). To analyze the MMP-2 expression, total RNA was extracted with the Qiangen RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The RNA concentrations were determined with an SD2000 microspectrophotometer (Bioprince, Atlanta, GA, USA). cDNA was synthesized from 2 μg of total RNA with an MMLV reverse transcriptase (Bioprince) using an oligo dT primer (Bioprince) at 65°C for 1 h. qRT-PCR was performed on the iQ5 multicolor Real-Time PCR detection system using an iQ SYBR Green Supermix (Bio-Rad). PCR amplification was performed using the following primer sets: MMP-2 5'-ttgactgtaagccgct-3', 5'-actcgtactctccctcg-3', β-actin 5'-ggacctgactgacttc-3', and 5'-aggctcttgaatctcgc-3'. The sample was normalized using the human β-actin gene as an endogenous control. For each sample, the relative abundance of the target mRNA was calculated from the CΔt values for both the target and endogenous reference gene using the 2−ΔΔCt cycle threshold method.

2.7. Enzyme-Linked Immunosorbent Assay (ELISA). The secreted MMP-2 was quantified using the Human MMP-2 ELISA Kit (ab100610, Abcam, Cambridge, UK) according to the manufacturer’s instruction, and the absorbance was measured with an ELISA Reader (μ-Quant, Bio-Tek Instruments, Winooski, USA) at 450 nm.

2.8. Intracellular Calcium Measurement. After removing the growth medium, the cells were washed with calcium-free HBSS (Invitrogen) and 20 mM HEPES assay buffer (pH 7.2, Invitrogen). The cells were then mixed with 100 μl of Fluo-4-NW-dye, obtained from Molecular Probes (Invitrogen), and incubated for 30 min at 37°C. Following an additional 30-min incubation at room temperature in the dark, the fluorescence signals were measured using the Cytomics FC500 MLP (Beckman Coulter Inc.) with appropriate for excitation and emission settings of 494 nm and 516 nm, respectively.
Figure 1: ATRA upregulates MMP-2 mRNA expression but suppresses its cell surface expression of THP-1. THP-1 cells were treated with the different concentrations of ATRA as indicated above for 24 h (a and c) or with 1 μM (b) or 100 nM (d) ATRA for various time points as indicated above. The expression of MMP-2 mRNA was determined by qRT-PCR and was normalized to that of β-actin (a and b). The cell surface expression of MMP-2 was analyzed by flow cytometry (c and d). Bar graphs show the relative gene expression ± SD. *p < 0.05 versus DMSO-treated control.

2.9. Statistical Analysis. All data were presented as mean ± standard deviation (SD), from at least three different experiments. The group means were compared using one-way analysis of variance (ANOVA), followed by post hoc test. All tests were performed using the SPSS statistical software version as mean ± SD. *p < 0.05 was considered statistically significant.

3. Results

3.1. ATRA Enhances MMP-2 mRNA Expression, but Reduces Cell Surface MMP2 Expression. We examined the effects of ATRA on MMP-2 expression in the human myeloid leukemic cell line THP-1. The cells were treated with different concentrations of ATRA, ranging from 0.1 to 1000 nM for 24 h, and the MMP-2 mRNA expression was determined by qRT-PCR. MMP-2 mRNA expression started to increase at ATRA concentration as low as 0.1 nM and peaked (3.7-fold increase) in the presence of 1 μM ATRA (Figure 1(a)). Thereafter, MMP-2 mRNA expression increased gradually, reaching approximately 5 times the control level at 48 h after treatment with 100 nM ATRA (Figure 1(b)). Since it is known that MMP-2 can be membrane-bound or secreted [33], we first examined the cell surface MMP-2 expression using flow cytometry. As shown in Figure 1(c), cell surface MMP-2 expression started to decrease at an ATRA concentration of 0.1 nM, decreasing gradually thereafter, and reaching 60% of control levels after 1 μM ATRA treatment (Figure 1(c)). Cell surface MMP-2 levels started to decrease 12 h after treatment with 100 nM ATRA, decreasing significantly thereafter, and reaching around 50% of the control level at 48 h after the treatment (Figure 1(d)).

3.2. ATRA Induces MMP-2 Secretion in Dose- and Time-Dependent Manners. To find the reason behind the reduction of the surface levels of MMP-2 by ATRA, despite MMP-2 mRNA upregulation, we measured MMP-2 secretion with both western blot and ELISA. The cells were treated with various concentrations of ATRA, ranging from 0.1 to 100 nM for 24 h and the culture supernatants were collected, concentrated by filtration, and subjected to western blot analysis. Secreted MMP-2 levels were markedly increased
by 0.1 nM ATRA treatment, with a maximum increase of 3700% at 100 nM ATRA concentration (Figures 2(a) and 2(d)). After treatment with 1 μM ATRA, secreted MMP-2 levels gradually increased over time, reaching approximately 1000% of the control level at 48 h, and decreased thereafter (Figures 2(b) and 2(e)). The increase in MMP-2 secretion, measured by western blot, was confirmed by ELISA which revealed similar patterns of increase in ATRA-induced MMP-2 secretion (Figures 2(f) and 2(g)). To confirm that the secreted MMP-2 was the active form, we performed gelatinase zymography, which is commonly utilized to detect the gelatinolytic enzymatic activities of the active forms of both MMP-2 and MMP-9. As shown in Figure 2(c), the protein band of the MMP-2 active form (molecular weight 68 kD) in the ATRA-treated cells was thicker than that in the DMSO-treated control cells, indicating that ATRA treatment induces the secretion of the active form of MMP-2.

3.3. ATRA-Induced MMP-2 Secretion Depends on the RAR/RXR Pathway. Since both RAR and RXR play critical roles in ATRA-regulated gene expression [34], we examined whether MMP-2 secretion is affected by RAR/RXR agonists or antagonists. The cells were treated with different concentrations of RAR/RXR agonist, ranging from 0.01 to 1 μM for 48 h in the absence of ATRA. The RAR agonist induced MMP-2 secretion in a concentration-dependent manner, whereas the effect of RXR agonist on MMP-2 secretion was only pronounced at a concentration of 1 μM (Figures 3(a)–3(c)). The levels of MMP-2 secretion, induced by treatment with 1 μM RAR agonist or RXR agonist, were comparable to those
induced by 100 nM ATRA treatment. To assess the effects of RAR/RXR antagonists on ATRA-induced MMP-2 secretion, the cells were treated with 1 μM RAR or RXR antagonist in the presence of 100 nM ATRA for 48 h. As shown in Figures 3(a) and 3(d), the RAR or RXR antagonist completely reversed ATRA-induced MMP-2 secretion.

3.4. ATRA-Induced MMP-2 Secretion Depends on Calcium Ions. Since several studies have suggested the possible relationship between cellular calcium levels and enhanced MMP expression [35–37], we examined the intracellular calcium levels of ATRA-treated cells and performed experiments with calcium-channel blocker to evaluate the possible involvement of calcium ions in ATRA-induced MMP-2 secretion. As shown in Figure 4(a), treatment with ATRA led to a marked increase in the intracellular calcium levels in a time-dependent manner. Verapamil, a calcium-channel blocker, significantly inhibited ATRA-induced MMP-2 secretion (Figures 4(b) and 4(c)), indicating the involvement of calcium ions in ATRA-induced MMP-2 secretion.

3.5. Dexamethasone Inhibits ATRA-Induced MMP-2 Secretion. Since it has been reported that the anti-inflammatory agent dexamethasone inhibits MMP-2 expression [27, 29] and cancer cell migration [38–40], we examined the effect of dexamethasone on ATRA-induced MMP-2 secretion in THP-1 cells. The cells were pretreated with dexamethasone at different concentrations for 2 h, followed by ATRA treatment for 48 h. The culture supernatants were concentrated and subjected to western blot analysis. As shown in Figure 5, 1 μM or 10 μM dexamethasone reversed ATRA-induced MMP-2 secretion, whereas 100 nM dexamethasone had no effect on it (Figures 5(a) and 5(b)). The significant suppression of ATRA-induced MMP-2 secretion, achieved by treating THP-1 cells with 1 μM or 10 μM dexamethasone, was also confirmed by ELISA (Figure 5(c)).

4. Discussion

ATRA is known to suppress various types of cancers [41]. The mechanisms of the anticancer effects of ATRA include antiproliferation, proapoptosis, and metastasis inhibition [42]. For tumor invasion and migration, the tumor cells must modulate matrix degradation, cell-cell adhesion, and cell-matrix attachment [43]. MMPs mediate the invasive properties of tumor cells and promote angiogenesis through their ability to degrade basement membranes and remodel the ECM architecture [44–46]. In particular, MMP-2 plays...
a critical role in tumor cell invasion and metastasis [17, 45–47]. Most previous studies demonstrated that ATRA exerts inhibitory effects on the MMP-2 expression of various tumor types [23–29]. However, our results revealed that ATRA enhances both MMP-2 expression and secretion in human myeloid leukemia THP-1 cells. The reason for the discrepancy between the previous results and our current findings is unknown; however, it may be attributed to the different tumor types used in the studies. Unlike our study, where leukemic cells with indigenous migratory and invasive properties were used, all the previous studies cited above used tumor cells derived from nonleukocytic cells.

Although ATRA is generally well tolerated, development of retinoic acid syndrome (RAS) in some patients has been recognized as a distinct potential life-threatening complication, which is characterized by fever, dyspnea, hypotension, and weight gain [48]. The histologic characteristics of RAS include organ infiltration by leukemic cells [49]. ATRA-induced leukemic cell extravasation was found to be due to the increased adhesion and motility of these cells compared with their undifferentiated counterparts [50–52]. Although the underlying molecular mechanisms for the emigration of ATRA-treated leukemic cells into tissues are yet to be elucidated, this syndrome was effectively treated by administering dexamethasone and by withholding ATRA in severe cases [53–55]. In our study, MMP-2 expression and secretion in THP-1 cells were markedly enhanced by ATRA treatment and pretreatment of THP-1 cells with dexamethasone significantly inhibited ATRA-induced secretion of MMP-2. Since it is known that dexamethasone upregulates glucocorticoid receptor to inhibit NF-κB activity [56], and that ATRA can induce NF-κB activation [57], which results in MMP-2 expression and activation [58], we speculate that inhibitory action of dexamethasone may be due to a suppressive effect on NF-κB activation. Based on our results, we suggest that ATRA-enhanced MMP-2 expression and secretion may be one of the major causes of RAS. However, to verify our hypothesis, further in vitro studies with matrigel invasion and transendothelial invasion assays using ATRA, RAR/RXR agonists or antagonists, and MMP-2 selective inhibitors, as well as animal studies, are necessary.

ATRA exerts various biological effects including regulation of gene expression by binding to the nuclear RARs [59, 60]. ATRA binds to RAR to form heterodimers with RXR. The RAR-RXR protein complex binds to retinoic acid response elements (RAREs) or retinoid X response elements (RXREs), each of which has a well-defined DNA sequence and induces gene transcription [61]. Our results revealed...
that the RAR agonist alone could induce MMP-2 secretion, while the RAR antagonist alone could reverse ATRA-induced MMP-2 secretion, suggesting that ATRA-enhanced MMP-2 expression and secretion depend on the RAR signaling pathway. However, since ATRA does not bind to RXR, our finding that the RXR agonist alone is able to induce MMP-2 secretion, which can be reversed by the RXR antagonist alone, is also indicative that MMP-2 secretion is independent of the RAR mechanisms. Since the RXR agonist, LG100268, used in this study, was capable of activating the PPARy-RXR heterodimers, PPARa-RXR heterodimers [62], and RXR homodimers [63], the MMP-2 secretion could be mediated by the RXR homodimer signaling pathway or PPAR-dependent mechanisms in addition to the RAR signaling pathway.

In this study, ATRA increased the intracellular calcium levels, and the calcium-channel blocker, verapamil, inhibited ATRA-induced MMP-2 secretion, suggesting that calcium influx is necessary for ATRA-induced MMP-2 secretion. Our results agree with that of the previous study, which showed that ATRA increased the intracellular calcium levels of human teratocarcinoma cells [64]. In that study, the authors demonstrated that the increase in intracellular calcium levels of ATRA-treated cells was due to increased expression of calcium channels. Our results are also in line with earlier findings that calcium ions are required to induce MMP-2 expression [65]. In addition, Zhang et al. demonstrated that enhanced levels of intracellular calcium ions and MMP-2 expression are associated with metastasis of lung cancer cells [66]. Taken together, our results suggest that ATRA induces calcium influx, which may be due to enhanced calcium-channel expression, and is involved in the induction of MMP-2 secretion in human myeloid leukemia THP-1 cells. However, the precise mechanisms of the ATRA-induced increase in intracellular calcium levels and MMP-2 secretion must be clarified in future studies.

In summary, our results show, for the first time, that ATRA enhances MMP-2 expression and secretion in human myeloid leukemia THP-1 cells in a calcium ion dependent manner through RAR-dependent and independent signaling pathways, and this enhanced secretion was reversed by dexamethasone treatment. We suggest that this enhanced expression and secretion of MMP-2 induced by ATRA treatment may be associated with the possible mechanisms of RAS.

Abbreviations

ATRA: All-trans retinoic acid
RAR: Retinoic acid receptor
RXR: Retinoid X receptor
MMP: Matrix metalloproteinase
RAS: Retinoic acid syndrome.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF funded by the Ministry of Education (NRF-2015R1A1A01059876).

References

[1] M. Clagett-Dame and H. F. DeLuca, “The role of vitamin A in mammalian reproduction and embryonic development,” Annual Review of Nutrition, vol. 22, pp. 347–381, 2002.

[2] C. B. Stephensen, “Vitamin A, infection, and immune function,” Annual Review of Nutrition, vol. 21, pp. 167–192, 2001.

[3] M. E. Huang, Y. C. Ye, S. R. Chen et al., “Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia,” Blood, vol. 72, pp. 567–572, 1988.

[4] S. Castaigne, C. Chomienne, M. T. Daniel et al., “All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results,” Blood, vol. 76, no. 9, pp. 1704–1709, 1990.

[5] F. Grignani, P. F. Ferrucci, U. Testa et al., “The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells,” Cell, vol. 74, no. 3, pp. 423–431, 1993.

[6] R. P. Warrell Jr., H. de The, Z.-Y. Wang, and L. Degos, “Acute promyelocytic leukemia,” The New England Journal of Medicine, vol. 329, no. 3, pp. 177–189, 1993.

[7] P. Fenaux, C. Chomienne, and L. Degos, “Acute promyelocytic leukemia: Biology and treatment,” Seminars in Oncology, vol. 24, no. 1, pp. 92–102, 1997.

[8] R. Nasr, V. Lallemand-Breitenbach, J. Zhu, M.-C. Guillemin, and H. De Thé, “Therapy-induced PML-RARA proteinolysis and acute promyelocytic leukemia cure,” Clinical Cancer Research, vol. 15, no. 20, pp. 6321–6326, 2009.

[9] J. Jing, C. Nelson, J. Paik, Y. Shirasaka, J. K. Amory, and N. Isoherranen, “Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions,” The Journal of Pharmacological and Experimental Therapeutics, vol. 361, no. 2, pp. 246–258, 2017.

[10] M. A. M. Ali, A. K. Chow, A. D. Kandasamy et al., “Mechanisms of cytosolic targeting of matrix metalloproteinase-2,” Journal of Cellular Physiology, vol. 227, no. 10, pp. 3397–3404, 2012.

[11] H.-J. Ra and W. C. Parks, “Control of matrix metalloproteinase catalytic activity,” Matrix Biology, vol. 26, no. 8, pp. 587–596, 2007.

[12] M. Anghelina, A. Schmeisser, P. Krishnan, L. Moldovan, R. H. Strasser, and N. I. Moldovan, “Migration of monocytes/macrophages in vitro and in vivo is accompanied by MMP12-dependent tunnel formation and by neovascularization,” Cold Spring Harbor Symposium on Quantitative Biology, vol. 67, pp. 209–215, 2002.

[13] L. Cao, C. Chen, H. Zhu et al., “MMP16 is a marker of poor prognosis in gastric cancer promoting proliferation and invasion,” Oncotarget, vol. 7, no. 32, pp. 51865–51874, 2016.

[14] A. Pardo, S. Cabrera, M. Maldonado, and M. Selman, “Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis,” Respiratory Research, vol. 17, no. 1, article no. 23, 2016.

[15] J. E. Kobliński, M. Ahram, and B. F. Sloane, “Unraveling the role of proteases in cancer,” Clinica Chimica Acta, vol. 291, no. 2, pp. 113–135, 2000.

[16] K. Nabeshima, T. Inoue, Y. Shimao, and T. Sameshima, “Matrix metalloproteinases in tumor invasion: role for cell migration,” Pathology International, vol. 52, no. 4, pp. 255–264, 2002.

[17] K. Kessenbrock, V. Plaks, and Z. Werb, “Matrix metalloproteinases: regulators of the tumor microenvironment,” Cell, vol. 141, no. 1, pp. 52–67, 2010.

[18] E. C. Finger and A. J. Giaccia, “Hypoxia, inflammation, and the tumor microenvironment in metastatic disease,” Cancer and Metastasis Reviews, vol. 29, no. 2, pp. 285–293, 2010.

[19] I. Massova, L. P. Kotra, R. Fridman, and S. Mobashery, “Matrix metalloproteinases: structures, evolution, and diversification,” The FASEB Journal, vol. 12, no. 12, pp. 1075–1095, 1998.

[20] A. Schröper, U. Kammerer, M. Kapp, J. Dietl, S. Feix, and J. Anacker, “Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines,” BMC Cancer, vol. 10, no. 1, p. 553, 2010.

[21] M. Okada, N. Murata, and H. Yamawaki, “Canstatin stimulates migration of rat cardiac fibroblasts via secretion of matrix metalloproteinase-2,” American Journal of Physiology-Cell Physiology, vol. 312, no. 3, pp. C199–C208, 2017.

[22] M. C. Bi, N. Hose, C. L. Xu et al., “Nonlethal Levels of Zexan-thin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-κB Pathway in Cultured Human Uveal Melanoma Cells,” Journal of Ophthalmology, vol. 2016, Article ID 8734309, 8 pages, 2016.

[23] A. Papi, G. Bartolini, C. Ammar et al., “Inhibitory effects of retinoic acid and IFN on growth, migration and invasiveness in the U87MG human glioblastoma cell line,” Oncology Reports, vol. 18, no. 4, pp. 1015–1021, 2007.

[24] M. W. Roomi, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “Modulation of MMP-2 and MMP-9 secretion by cytokines, inducers and inhibitors in human glioblastoma T-98G cells,” Oncology Reports, vol. 37, no. 3, pp. 1907–1913, 2017.

[25] A. Dutta, T. Sen, A. Banerji, S. Das, and A. Chatterjee, “Studies on multifunctional effect of all-trans retinoic acid (ATRA) on matrix metalloproteinase-2 (MMP-2) and its regulatory molecules in human breast cancer cells (MCF-7),” Journal of Oncology, vol. 2009, Article ID 627840, 13 pages, 2009.

[26] M. W. Roomi, J. C. Monterrey, T. Kalinovsky, A. Niedzwiecki, and M. Rath, “Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines,” Oncology Reports, vol. 22, no. 6, pp. 1283–1291, 2009.

[27] M. W. Roomi, J. C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors,” Oncology Reports, vol. 23, no. 3, pp. 605–614, 2010.

[28] M. W. Roomi, T. Kalinovsky, J. Monterrey, M. Rath, and A. Niedzwiecki, “In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors,” International Journal of Oncology, vol. 43, no. 6, pp. 1787–1798, 2013.

[29] M. W. Roomi, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors,” International Journal of Oncology, vol. 44, no. 1, pp. 27–34, 2014.

[30] A.-M. Chambaut-Guérin, S. Hérigault, P. Rouet-Benzineb, C. Isoherranen, “Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions,” The Journal of Pharmacological and Experimental Therapeutics, vol. 361, no. 2, pp. 246–258, 2017.
[31] H. J. Lee, M. K. Park, H. Bae, H. Yoon, S. Kim, and C. Lee, “Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway,” Biomolecules & Therapeutics, vol. 20, no. 3, pp. 286–292, 2012.

[32] A. Safina, M.-Q. Ren, E. Vandette, and A. V. Bakin, "TAK1 is required for TGF-β-stimulated regulation of matrix metalloproteinase-9 and metastasis," Oncogene, vol. 27, no. 9, pp. 1198–1207, 2008.

[33] Y. Itoh, A. Ito, K. Iwata, K. Tanzawa, Y. Mori, and H. Nagase, "Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface," The Journal of Biological Chemistry, vol. 273, no. 38, pp. 24360–24367, 1998.

[34] P. Chambon, "A decade of molecular biology of retinoic acid receptors," The FASEB Journal, vol. 10, no. 9, pp. 940–956, 1996.

[35] T. Kobayashi, S. Hattori, Y. Nagai, T. Tajima, and T. Nishikawa, "Differential regulation of MMP-2 and MMP-9 gelatinases in cultured human keratinocytes," Dermatology, vol. 197, no. 1, pp. 1–5, 1998.

[36] T. Kobayashi, S. Hattori, Y. Nagai, and T. Tajima, "Differential regulation of the secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 from human keratinocytes in culture," IUBMB Life, vol. 50, no. 3, pp. 221–226, 2000.

[37] T. Kobayashi, J. Kishimoto, Y. Ge et al., "A novel mechanism of matrix metalloproteinase-9 gene expression implies a role for keratinization," EMBO Reports, vol. 2, no. 7, pp. 604–608, 2001.

[38] T. Mayanagi, T. Morita, K. Hayashi, K. Fukumoto, and K. Sobue, "Glucocorticoid receptor-mediated expression of caldesmon regulates cell migration via the reorganization of the actin cytoskeleton," The Journal of Biological Chemistry, vol. 283, no. 45, pp. 31883–31896, 2008.

[39] X.-G. Meng and S.-W. Yue, "Dexamethasone disrupts cytoskeleton organization and migration of breast cancer cells by modulating the AKT/mTOR/RhoA pathway," Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 10245–10250, 2014.

[40] E. R. Fietz, C. R. Keenan, G. López-Campos et al., "Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential," Scientific Reports, vol. 7, no. 1, 2017.

[41] M. C. Chen, S. L. Hsu, H. Lin, and T. Yang, "Retinoic acid and cancer treatment," Biomedicine, vol. 4, p. 22, 2014.

[42] F. Alizadeh, A. Bolhasani, A. Khavari, S. Z. Bathiaie, T. Naji, and S. A. Bidgoli, "Retinoids and their biological effects against cancer," International Immunopharmacology, vol. 18, no. 1, pp. 43–49, 2014.

[43] E. I. Deryugina and J. P. Quigley, "Matrix metalloproteinases and tumor metastasis," Cancer and Metastasis Reviews, vol. 25, no. 1, pp. 9–34, 2006.

[44] H. Nagase and J. F. Woessner Jr., "Matrix metalloproteinases," The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999.

[45] W. Hornebeck, H. Emonard, J.-C. Monboisse, and G. Bellon, "Matrix-directed regulation of pericellular proteolysis and tumor progression," Seminars in Cancer Biology, vol. 12, no. 3, pp. 231–241, 2002.

[46] M. Selki, "Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion," Cancer Letters, vol. 194, no. 1, pp. 1–11, 2003.

[47] S. L. Parsons, S. A. Watson, H. M. Collins, N. R. Griffin, P. A. Clarke, and R. J. C. Steele, "Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy," British Journal of Cancer, vol. 78, no. 11, pp. 1495–1502, 1998.

[48] N. Cox and H. O’Brien, "Sweet’s syndrome associated with trans-retinoid acid treatment in acute promyelocytic leukemia," Clinical and Experimental Dermatology, vol. 19, no. 1, pp. 51–52, 1994.

[49] S. R. Frankel, A. Eardley, G. Lauwers, M. Weiss, and R. P. Warrell Jr., "The retinoid acid syndrome in acute promyelocytic leukemia," Archives of Internal Medicine, vol. 117, no. 4, pp. 292–296, 1992.

[50] G. Taraboletti, P. Borsotti, R. G. S. Chirivi et al., "Effect of all-trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells," International Journal of Cancer, vol. 70, no. 1, pp. 72–77, 1997.

[51] D. C. Brown, H. Tsuji, and R. S. Larson, "All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukemia cell line NB-4 under physiologic flow," British Journal of Haematology, vol. 107, no. 1, pp. 86–98, 1999.

[52] C. Zang, L. Hongyu, C. Reis, M. G. Ismair, and P. E. Petrides, "Enhanced migration of the acute promyelocytic leukemia cell line NB-4 under in vitro conditions during short-term all-trans-retinoic acid treatment," Journal of Cancer Research and Clinical Oncology, vol. 126, no. 1, pp. 33–40, 2000.

[53] L. Vahdat, P. Maslak, W. H. Miller Jr. et al., "Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD3 expression in patients treated with all-trans retinoic acid," Blood, vol. 84, no. 11, pp. 3843–3849, 1994.

[54] R. P. Warrell Jr., P. Maslak, A. Eardley, G. Heller, W. H. Miller Jr., and S. R. Frankel, "Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience," Leukemia, vol. 8, no. 6, pp. 929–933, 1994.

[55] M. R. Nicolls, L. S. Terada, R. M. Tudor, S. A. Prindiville, and M. I. Schwarz, "Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome," American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 4, pp. 1302–1305, 1998.

[56] A. E. Coutinho and K. E. Chapman, "The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights," Molecular and Cellular Endocrinology, vol. 335, no. 1, pp. 2–13, 2011.

[57] A. R. Farina, M.-P. Masciulli, A. Tacconelli et al., "All-trans retinoic acid induces nuclear factor κB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma cells," Cell Growth & Differentiation, vol. 13, no. 8, pp. 343–354, 2002.

[58] Y.-Q. Lan, C. Zhang, J.-H. Xiao et al., "Suppression of IκBα increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells," Molecular Vision, vol. 15, pp. 1977–1987, 2009.

[59] M. M. Aagaard, R. Siersbæk, and S. Mandrup, "Molecular basis for gene-specific transactivation by nuclear receptors," Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 824–835, 2011.

[60] M. Tsai and B. W. O’Malley, "Molecular mechanisms of action of steroid/thyroid receptor superfamily members," Annual Review of Biochemistry, vol. 63, pp. 451–486, 1994.

[61] P. Chambon, A. Ze lent, M. Petkovich et al., "The family of retinoic acid nuclear receptors," in Retinoids: 10 Years On, L.-H. Sanrat, Ed., pp. 10–27, Karger/Basel, 1991.
[62] R. Mukherjee, J. Strasser, L. Jow, P. Hoener, J. R. Paterniti, and R. A. Heyman, “RXR Agonists Activate PPARα-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 2, pp. 272–276, 1998.

[63] D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.

[64] Z.-Y. Gao, G. Xu, M. M. Stwora-Wojczyk, F. M. Matschinsky, V. M.-Y. Lee, and B. A. Wolf, “Retinoic acid induction of calcium channel expression in human NT2N neurons,” Biochemical and Biophysical Research Communications, vol. 247, no. 2, pp. 407–413, 1998.

[65] E. C. Kohn, W. Jacobs, Y. S. Kim et al., “Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A),” Journal of Biological Chemistry, vol. 269, pp. 21505–21511, 1994.

[66] J. Zhang, G. Liu, Y. Meng, H. Lin, and Y. Lu, “MAG-2 promotes invasion, mobility and adherence capability of lung cancer cells by MMP-2, CD44 and intracellular calcium in vitro,” Oncology Reports, vol. 21, no. 3, pp. 697–706, 2009.